TY - JOUR T1 - Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 657 LP - 658 DO - 10.3899/jrheum.181246 VL - 46 IS - 6 AU - ARTHUR WEINSTEIN AU - BRIAN McEVILLY AU - THIERRY DERVIEUX Y1 - 2019/06/01 UR - http://www.jrheum.org/content/46/6/657.abstract N2 - To the Editor:The article by Alemao, et al1 documented that acceleration of treatment regimens for 3458 biologic-naive patients with rheumatoid arthritis (RA) did not significantly differ based on the presence or absence of poor prognostic factors (PPF). These findings suggest that, for whatever reason, clinicians were unable to translate PPF into a more aggressive therapeutic approach. Further, this occurred even though patients with a high initial PPF fared worse over a 12-month period in achieving low disease activity and maintaining employment. The reasons for this lack of translation by clinicians of PPF to more aggressive treatment is uncertain. The more recent focus on “treat to target,” evident in the 2015 American College of Rheumatology treatment recommendations, addresses high disease activity but does not directly address the role of other prognostic factors. This study suggests that treating to … Address correspondence to B. McEvilly, 1261 Liberty Way, Vista, California 92081, USA. E-mail: Mcevilly7{at}yahoo.com ER -